Sinopharm’s COVID-19 vaccine candidate has triggered antibody responses in early-stage trials.

Almost all participants in the phase 1 and 2 trials who received the vaccine had an antibody response. The phase 1 trial tested three different doses in 96 participants, while the phase 2 study tested a medium dose in 224 participants.

Sinopharm’s COVID-19 vaccine is currently in phase 3 testing in the United Arab Emirates.